TIVICAY contains dolutegravir in the form of dolutegravir sodium, and it belongs to the class of HIV integrase strand transfer inhibitors (INSTIs). It is available as film-coated tablets in strengths equivalent to 10 mg, 25 mg, or 50 mg of dolutegravir free acid for oral administration, and as tablets for oral suspension equivalent to 5 mg of dolutegravir free acid. Key inactive ingredients include D-mannitol, microcrystalline cellulose, and povidone K29/32.
How should I use this medication?
Take this medication by mouth with water. You can take it with or without food. If it upsets your stomach, take it with food. Talk to your pharmacist about when to take your medications. Some medications must be separated from this one by several hours. For your therapy to work as well as possible, take each dose exactly as prescribed on the prescription label. Do not skip doses. Skipping doses can make the HIV virus resistant to this and other medications. Keep taking this therapy unless your care team tells you to stop. Talk to your care team about the use of this medication in children. While this medication may be prescribed for selected conditions, precautions do apply.
Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once. NOTE: This medicine is only for you. Do not share this medicine with others.
What if I miss a dose?
If you miss a dose, take it as soon as you can. If it is almost time for your next dose, take only that dose. Do not take double or extra doses.
Where should I keep my medication?
Keep out of the reach of children and pets. You will be instructed on how to store this medication.
NOTE: This sheet is a summary. It may not cover all possible information. If you have questions about this medicine, talk to your doctor, pharmacist, or health care provider.
What side effects may I notice from receiving this medication?
Side effects that you should report to your care team as soon as possible: -Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat -Infection—fever, chills, cough, or sore throat -Liver injury—right upper belly pain, loss of appetite, nausea, light-colored stool, dark yellow or brown urine, yellowing skin or eyes, unusual weakness or fatigue Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome): -Fatigue -Headache -Nausea -Trouble sleeping -Worsening mood, feelings of depression
This list may not describe all possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What should I tell my care team before I take this medication?
They need to know if you have any of these conditions: -Liver disease -An unusual or allergic reaction to dolutegravir, other medications, foods, dyes, or preservatives -Pregnant or trying to get pregnant -Breast-feeding
What may interact with this medication?
Do not take this medication with any of the following: -Dofetilide This medication may also interact with the following: -Antiviral medications for HIV or AIDS, such as efavirenz, etravirine, nevirapine, fosamprenavir;ritonavir, tipranavir;ritonavir -Buffered medications, such as buffered aspirin -Calcium supplements -Certain antacids -Certain laxatives -Certain medications for seizures, such as carbamazepine, oxcarbazepine, phenytoin, phenobarbital -Iron supplements -Metformin -Rifampin -St. John's wort -Sucralfate
This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.
What should I watch for while using this medication?
Visit your care team for regular checks on your progress. Discuss any new symptoms with your care team. You will need to have important blood work done while taking this medication. HIV is spread to others through sexual or blood contact. Talk to your care team about how to stop the spread of HIV. Talk to your care team if you wish to become pregnant or think you might be pregnant. This medication can cause serious birth defects.
Source: This information is sourced from Elsevier Inc.
The reviews, ratings, comments, and opinions expressed on this platform are solely those of the individual medical professionals who posted them and do not reflect the views or positions of Sermo, Inc. Sermo does not endorse, verify, or validate the content of individual reviews. The information provided is user-generated and reflects personal clinical experiences, which may not be complete, accurate, or applicable to your specific health needs. It is not intended as medical advice.
Prescription medications affect individuals differently, and what works for one person may not work for another. Always consult your doctor, pharmacist, or other qualified healthcare provider to ensure the information displayed applies to your personal circumstances. Only a licensed healthcare provider can advise you on what is safe and effective for you.
Keep all medications out of the reach of children, never share your medicine with others, and use each medication only as prescribed. Your reliance on any information provided on this platform is at your own risk.
Sermo Drug Ratings, and all information provided on this website, may not be used in combination with any artificial intelligence tool (including to train an algorithm, test, process, analyze, generate output and/or develop any form of artificial intelligence tool).
Visitors to the online patient-facing website at Sermo.com (“Sermo Drug Ratings”) are Authorized Users of the website, which contains data owned by a third-party provider, Elsevier, Inc. Accordingly, by visiting Sermo Drug Ratings, Authorized User acknowledges that the website includes Elsevier owned data that Sermo licenses pursuant to a separate usage and Data agreement (the “Agreements”). Authorized User further acknowledges that Sermo is a third-party beneficiary of the Agreements and Authorized User’s use of the website hereby binds them to the terms of the Agreements; provided, however, that Elsevier shall have no obligations or liability to an Authorized User whatsoever pursuant to the terms of the Agreements.